Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 7INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Head & Neck 1Breast 1

Conditions

Breast Neoplasms 40Neoplasms 8Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Quality of Life 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Hot Flashes 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Gynecomastia 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Diseases 1Breast Cancer Subjects 1Breast Cancer Metastatic 1Breast Cancer Female 1Bone Density 1Advanced Metastatic Breast Cancer 1Advanced Cancer 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × Tamoxifen × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT01685255 2019-03-11

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Incyte Corporation

Phase 2 Terminated
83 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡